


Express Mail Label No.: EK 151360US

Date of Deposit: December 21, 2000

Attorney Docket No. 21486-026 CIP



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Gregory A. Jay

ASSIGNEE: Rhode Island Hospital, A Lifespan Partner

SERIAL NUMBER: 09/556,246

EXAMINER: J. Kerr

FILING DATE: April 24, 2000

ART UNIT: 1633

FOR: TRIBONECTINS

RECEIVED

05 2001

TECH CENTER 1600/2900

December 21, 2000

Boston, Massachusetts

Box SEQUENCE

Assistant Commissioner for Patents

Washington, D.C. 20231


**SUBMISSION OF PAPER COPY AND/OR COMPUTER-READABLE
COPY OF SEQUENCE LISTING FOR INVENTION CONTAINING
NUCLEOTIDE AND/OR AMINO ACID SEQUENCE**

1. ☒ This paper is in response to the Patent Office letter dated August 22, 2000.
☐ A copy of the Patent Office letter is enclosed.

Note: If these papers are filed before the Patent Office letter is mailed, the adequate identification of the original papers should be made, e.g., in addition to the name of the inventor and title of the invention, the filing date on the Express Mail Label, the USSN from the return postcard or the attorney's docket number must be added.

- ☒ This paper is in compliance with the requirements for patent applications containing nucleotide sequences and/or amino acid sequence disclosures.
2. Submitted herewith are:
- ☐ A Preliminary Amendment directing entry of the Sequence Listing into the specification;
 - ☒ a paper copy of the Sequence Listing for the above-identified patent application with each sequence assigned a separate identifier; and
 - ☒ a copy of the Sequence Listing in computer-readable form for the above-identified patent application.

APPLICANTS: Gregory D.
U.S.S.N.: 09/556,246



RECEIVED

JAN 10 2001

TECH CENTER 1000/2200


3. **Statement:**

I hereby state that: *(complete applicable items - A, B and/or C)*

- A. ☒ The content of the paper and computer-readable copies of the Sequence Listing submitted herewith are the same.
- B. ☐ The content of the computer-readable copy of the Sequence Listing submitted herewith is the same as the Sequence Listing appearing at the end of the originally-filed specification.
- C. ☒ This submission includes no new matter.

Applicants believe that no fee is required for the filing of the present submission. However, the Commissioner is hereby authorized to charge any additional fees that may be due, or credit any overpayment, to Deposit Account No. 50-0311, Ref. No. 21486-026 CIP.


Respectfully submitted,

 Reg. No. 42,306

Ingrid A. Beattie, Reg. No. 42,306
Attorney(s) for Applicants
c/o MINTZ, LEVIN
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

Dated: December 21, 2000

TRADOCS:1414466.1(%B#Q011.DOC)



Application No.: 09/556,246

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☒ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: the topology of the sequence was not reported.

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

RECEIVED

JAN 10 2001

TECH CENTER 1600/2900

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For Patent/In software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE